Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Godaddy Inc (GDDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Godaddy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Godaddy Inc trades at $90.75 (market cap $11.49B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.6× Godaddy Inc's market cap, and Godaddy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GDDY | |
|---|---|---|
Market Cap | $29.60B | $11.49B |
Sector | Health | Technology |
52-Week High | $491.22 | $148.88 |
52-Week Low | $205.48 | $75.07 |
Enterprise Value | $27.56B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
GoDaddy (GDDY) trades at $91.81, up 0.34% today, with a bearish technical signal but strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and a P/E of 13.48, indicating potential undervaluation. However, recent news highlights multiple securities investigations, creating investor uncertainty. Revenue growth is steady, projected at $5.1B for 2026, while cash flow trends improved in 2024 before a slight dip in 2025.
The stock presents a mixed outlook: analyst consensus is bullish with a $112.13 price target (21 buys, 15 holds, 1 sell), but technical indicators and legal risks weigh on near-term sentiment. Key opportunities include consistent earnings outperformance and solid profitability, while risks involve ongoing legal probes and high debt levels. Investors should balance fundamental strength against headline volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
